ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Diabetes"

  • Abstract Number: 2366 • 2019 ACR/ARP Annual Meeting

    Comparison of Healthcare Resource Utilization (HCRU) and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Switch to Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs

    Vardhaman Patel1, Zulkarnain Pulungan 2, Anne Shah 2, Barton Jones 2, Allison Petrilla 2, Leticia Ferri 3, Xue Han 3 and Kaleb Michaud 4, 1Bristol-Myers Squibb, New York City, NY, 2Avalere, washington, DC, 3Bristol-Myers Squibb Company, Princeton, NJ, 4University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Patients with RA experienced an increase in the whole-body insulin sensitivity and a reduction in HbA1c levels from treatment with abatacept, which is a…
  • Abstract Number: 2391 • 2019 ACR/ARP Annual Meeting

    Effect of Biologics on the Hemoglobin A1c in a Population of Rheumatoid Arthritis Patients

    Ana Goico 1, Anoka Martis1, Chistopher Kabir 1, David Mael 1 and Shoeb Mohammed 1, 1Advocate Illinois Masonic Medical Center, Chicago, IL

    Background/Purpose: Tumor necrosis factor (TNF), a pathogenic inflammatory mediator in Rheumatoid Arthritis (RA), has been shown to play an essential role in the pathophysiology of insulin resistance.…
  • Abstract Number: 839 • 2019 ACR/ARP Annual Meeting

    Disease Activity, Cytokine Profiles, and the Risk of Incident Diabetes in Rheumatoid Arthritis

    Joshua Baker1, Bryant England 2, Michael George 3, Grant Cannon 4 and Ted Mikuls 5, 1University of Pennsylvania, Philadelphia, PA, 2VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, 3University of Pennsylvania, Philadelphia, 4Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, 5VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis is associated with a higher risk of diabetes mellitus (DM) and cardiovascular disease. While disproportional obesity and visceral fat accumulation may contribute…
  • Abstract Number: 1409 • 2019 ACR/ARP Annual Meeting

    Comparison of Healthcare Resource Utilization and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Initiated Treatment with Abatacept versus Other Targeted Disease-Modifying Anti-Rheumatic Drugs

    Vardhaman Patel1, Zulkarnain Pulungan 2, Anne Shah 2, Barton Jones 2, Allison Petrilla 2, Leticia Ferri 3, Xue Han 3 and Kaleb Michaud 4, 1Bristol-Myers Squibb, New York City, NY, 2Avalere, washington, DC, 3Bristol-Myers Squibb Company, Princeton, NJ, 4University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Use of abatacept, a targeted DMARD (tDMARD), in patients with RA has shown to improve whole-body insulin sensitivity and reduce HbA1c levels.1  Comparative evidence…
  • Abstract Number: 1977 • 2019 ACR/ARP Annual Meeting

    The Synthesis of Hydrogen Sulfide Is Impaired in Osteoarthritic Chondrocytes from Diabetic Patients and in Vitro in Cells Under High Glucose Environment

    Carlos Vaamonde-García1, Tamara Hermida-Gómez 2, Francisco J. Blanco 3, Elena F Burguera 3 and Rosa Meijide-Faílde 1, 1Tissue Engineering and Regenerative Medicine Group. University of A Coruña, A Coruña, Spain, 2Unidad de Bioingeniería Tisular y Terapia Celular (GBTTC-CHUAC). Grupo de Investigación en Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC). Sergas. Centro de Investigaciones Científicas Avanzadas (CICA), A Coruña, Spain, 3Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain

    Background/Purpose: A growing number of findings indicates that type 2 diabetes is an independent risk factor of osteoarthritis (OA). However, the mechanisms underlying the connection…
  • Abstract Number: PP02 • 2018 ACR/ARHP Annual Meeting

    Sustained Weight Loss Managed by Multiple Medical Specialists

    Lawrence Phillips, Arthritis Foundation, Atlanta, GA

    Background/Diagnosis: A patient who was diagnosed in 1974 with type 1 diabetes and in 2000 with rheumatoid arthritis weighed 366 pounds in 2014. He found…
  • Abstract Number: 223 • 2018 ACR/ARHP Annual Meeting

    The Effect of Concomitant Diabetes on RA-Related Outcomes: Results from the Acr’s RISE Registry

    Huifeng Yun1, Fenglong Xie1, Lang Chen1, Shuo Yang1, Leticia Ferri2, Evo Alemao2, Tammy Curtice2 and Jeffrey R. Curtis1, 1University of Alabama at Birmingham, Birmingham, AL, 2Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: The impact of concomitant comorbidities on RA outcomes is of high interest, and some evidence suggests that patients (pts) with RA and diabetes may…
  • Abstract Number: 503 • 2018 ACR/ARHP Annual Meeting

    Waist Circumference Based Abdominal Obesity Versus Body Mass Index in Rheumatoid Arthritis: Influence on the Risk of Diabetes and Cardiovascular Disease

    Gulsen Ozen1, Sofia Pedro2 and Kaleb Michaud1,2, 1Rheumatology, University of Nebraska Medical Center, Omaha, NE, 2FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS

    Background/Purpose: Adipose tissue deposited around the mesentery is highly associated with insulin resistance and cardiovascular disease (CVD). Compared to BMI, waist circumference (WC) has been…
  • Abstract Number: 1276 • 2018 ACR/ARHP Annual Meeting

    Effect of Colchicine on Diabetes Incidence Among Gout Patients in a Veterans’ Affairs Population

    Anastasia Slobodnick1, Virginia Pike2, Michael Toprover1 and Michael Pillinger1, 1Medicine/Rheumatology, NYU School of Medicine, New York, NY, 2Medicine/Rheumatology, New York Harbor VA Healthcare System, New York, NY

    Background/Purpose: Previous studies suggest that patients with gout are at increased risk for developing diabetes.1 One possible explanation for this increased risk is the activation…
  • Abstract Number: 1534 • 2018 ACR/ARHP Annual Meeting

    Comparative Risk of Diabetes Mellitus in Rheumatoid Arthritis Patients Treated with Different Biologics- a Cohort Study

    Rishi J. Desai1, Sara Dejene2, Yinzhu Jin2, Jun Liu3 and Seoyoung C. Kim2, 1Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Patients with rheumatoid arthritis (RA) often develop diabetes mellitus (DM), potentially due to aggravated systemic inflammation. Reducing inflammation with disease-modifying antirheumatic drugs (DMARD) may…
  • Abstract Number: 1548 • 2018 ACR/ARHP Annual Meeting

    Favorable Effect of Hydroxychloroquine in Patients with Rheumatoid Arthritis and Diabetes or Impaired Glucose Control

    Farhana Polara, Mohmed Imran Gora and Shante Hinson, Internal Medicine, Lincoln Medical and Mental hospital, Bronx, NY

    Background/Purpose: Hydroxychloroquine (HCQ) is widely prescribed for patients with Rheumatoid Arthritis (RA) and Systemic Lupus Erythromatus (SLE). It is fairly well tolerated with multiple well…
  • Abstract Number: 1550 • 2018 ACR/ARHP Annual Meeting

    Improvement of HbA1c in Patients with Rheumatoid Arthritis and Diabetes Type 2 during Treatment with Tocilizumab

    Christof Specker1, Annette Alberding2, Martin Aringer3, Gerd R. Burmester4, Jan-Paul Flacke5, Michael Hofmann6, Peter Kaestner7, Herbert Kellner8, Frank Moosig9, Maren Sieburg10, Hans-Peter Tony11 and Gerhard Fliedner12, 1Rheumatology and Clinical Immunology, Universitätsklinikum Essen, Essen, Germany, 2Internal Rheumatology, Krankenhaus St. Josef, Wuppertal, Germany, 3Medicine III, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, 4Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, 5Rheumatology, Roche Pharma AG, Grenzach-Wyhlen, Germany, 6Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, 7Rheumatology, Ambulantes Rheumazentrum, Erfurt, Germany, 8Ambulantes Rheumazentrum, Erfurt, Germany, 9Rheumatology Center Schleswig-Holstein Mitte, Neumuenster, Germany, 10Rheumatologische Gemeinschaftspraxis, Magdeburg, Germany, 11Rheumatology/Immunology, Medizinische Klinik II, Universitätsklinik, Würzburg, Germany, 12Rheumatological Practice, Osnabrueck, Germany

    Background/Purpose: Interleukin 6 (IL-6) and C-reactive protein (CRP) are independent risk factors for type 2 diabetes mellitus [1], and IL-6 plays a role in insulin…
  • Abstract Number: 1880 • 2018 ACR/ARHP Annual Meeting

    Cardiovascular (CV) Risk Factors and Atherosclerotic CV Events Among Incident Cases of Systemic Sclerosis: Results from a Population Based Cohort (1980-2016)

    Avneek Singh Sandhu1, Reto Kurmann2, Cynthia S. Crowson3, Rekha Mankad2, Eric L. Matteson4, Thomas Osborn1, Kenneth J. Warrington5 and Ashima Makol1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 4Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, 5Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN

    Background/Purpose: Cardiac involvement, due to impairment of coronary microcirculation and myocardial fibrosis, affects prognosis in individuals with SSc, and represents one of the leading causes…
  • Abstract Number: 1957 • 2018 ACR/ARHP Annual Meeting

    Peri-Operative Glycemic Evaluation Prior to Total Joint Replacement in Patients with and without Diabetes

    Lindsey A. MacFarlane1, Yinzhu Jin2, Patricia D. Franklin3, Joyce Lii4, Jeffrey N. Katz5 and Seoyoung C. Kim6, 1Rheumatology, Brigham & Women's Hospital, Boston, MA, 2Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worchester, MA, 4Brigham and Women'a Hospital, Boston, MA, 5Brigham & Women's Hospital and Harvard Medical School, Boston, MA, 6Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Elevated hemoglobin A1c (HbA1c) has been associated with a 9-fold increase in wound complications after total joint replacement (TJR). Data suggest that including HbA1c…
  • Abstract Number: 2587 • 2018 ACR/ARHP Annual Meeting

    The Impact of Tumor Necrosis Factor Inhibitors on Diabetes Mellitus Among Patients with Inflammatory Arthritis

    Santhi Mantravadi1, Michael D. George2 and Alexis Ogdie3, 1Department of Clinical Pharmacology, Division of Rheumatology, Jefferson University School of Medicine, University of Pennsylvania, Philadelphia, PA, 2Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 3Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose:  Tumor necrosis factor (TNF) is a key inflammatory cytokine in the pathogenesis of psoriatic arthritis (PsA), RA, ankylosing spondylitis (AS), and diabetes mellitus (DM). …
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology